DRKS00016070
Recruiting
Not Applicable
ERASE_Evaluation of early treatment response of soft tissue sarcomas under neoadjuvant hyperthermia and chemotherapy using functional MRI as well as FDG PET-CT - ERASE
Klinikum der Universität München, Campus Großhadern0 sites35 target enrollmentFebruary 8, 2023
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- C41.9
- Sponsor
- Klinikum der Universität München, Campus Großhadern
- Enrollment
- 35
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Soft tissue sarcoma of the extremities in tumor stage AJCC III with indication for neoadjuvant combined chemotherapy/hyperthermia
- •\- Tumor board decision for treatment chemotherapy/hyperthermia
- •\- Indication for MRI and PET\-CT examinations as part of clinical care for soft tissue sarcoma
- •\- \> 18 years male/female
- •\- GFR value \>30ml/min
- •\- Signed declaration of consent
Exclusion Criteria
- •\- Contraindications to MRI examination, especially implants not suitable for MR, tattoos or piercings, pronounced claustrophobia
- •\- Lack of consent and/or lack of ability to consent to the study
- •\- Pregnancy
- •\- Known allergy to MR contrast agent or PET\-CT tracer
- •\- GFR \< 30 ml/min with renal insufficiency
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Evaluation of early treatment response and volumetric dose evaluation to target and organ at risk (small bowel/bladder/rectum) during radiation therapy of cervical cancer.Health Condition 1: null- GOODHealth Condition 2: C539- Malignant neoplasm of cervix uteri, unspecifiedCTRI/2022/03/040851AIIMS21
Completed
Not Applicable
Early evaluation of therapy response (targeted therapy and immunotherapy) in patients with metastasized malignant melanoma by multiparametric PET/MR imaging.C43.9Malignant melanoma of skin, unspecifiedDRKS00013925niversitätsklinikum Tübingen, Radiologische Klinik, Diagnostische & Interventionelle Radiologie62
Active, not recruiting
Not Applicable
Assessment of the early efficacy response rate of leflunomide according to the initial dosing regimen in the treatment of naive - DMARD early RA-patients. - LEADERPatients with a diagnosis of early active rhematoid arthritis in the previous 6 months, naive of previous treatment by DMARD and who need to be treated by DMARD.MedDRA version: 9.1Level: LLTClassification code 10039073Term: Rheumatoid arthritisEUCTR2007-000886-40-ITsanofi-aventis Groupe200
Active, not recruiting
Not Applicable
Assessment of the early efficacy response rate of leflunomide according to the initial dosing regimen in the treatment of naïve-DMARD early RA-patients. - LEADERpatients with a diagnosis of early active rheumatoid arthritis in the previous 6 months, naïves of previous treatment by a DMARD and who need to be treated by a DMARDMedDRA version: 9.1Level: LLTClassification code 10039073Term: Rheumatoid arthritisEUCTR2007-000886-40-PTsanofi-aventis groupe200
Active, not recruiting
Phase 1
Assessment of the early efficacy response rate of leflunomide according to the initial dosing regimen in the treatment of naïve-DMARD early RA-patients. - LEADERpatients with a diagnosis of early active rheumatoid arthritis in the previous 6 months, naïves of previous treatment by a DMARD and who need to be treated by a DMARDMedDRA version: 9.1Level: LLTClassification code 10039073Term: Rheumatoid arthritisEUCTR2007-000886-40-CZsanofi-aventis groupe200